Ocugen, Inc. Loss Submission Form
Company: Ocugen, Inc.
Ticker: (NASDAQ) OCGN
Deadline
Passed
Lead Plaintiff Deadline: August 17, 2021
Never Miss Another Deadline
Choose your preferred way to stay informed of new case launches and settlement deadlines.
Get Updates by Email
Subscribe for email notifications.
Allegations
(i) the information submitted to the U.S. Food and Drug Administration (“FDA”) was insufficient to support an Emergency Use Authorization (“EUA”), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Ocugen’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.